1. Nature Biotechnology published the letter, which 165 biotech executives signed, that details the industry’s “deep concern and opposition to the executive order.” 2. The letter says of the nearly 69 ...
Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary ...
Welcome to another edition of Core Biotech!I started this portfolio with the objective of proving that Long-Term investing in the biotech sector is a worthwhile endeavor.New buys and sells are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results